DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
MIRROR
Evaluation of a Generative Artificial Intelligence (AI) and Natural Language Processing (NLP) tool to obtain clinical data from electronic health records (EHRs) versus manual data capture in Oncology Clinical Trials: The MIRROR study.
BREAST
AIME
2024
PHERGAIN
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial
BREAST
(Journal) European Journal of Nuclear Medicine and Molecular Imaging
2024
ORPHEUS
Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study
PENILE
(Journal) European Urology Oncology
2024
DEBBRAH
Trastuzumab deruxtecan in patients with leptomeningeal carcinomatosis from HER2-positive and HER2-low advanced breast cancer: The DEBBRAH Trial
BREAST
(Journal) Med
2024
PRIMED
Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.
BREAST
ASCO
2024
DXCARTES
Neoadjuvant letrozole and palbociclib in HR-positive/HER2-negative and Oncotype DX® RS result ≥18 early breast cancer patients: DxCARTES study
BREAST
(Journal) ESMO Open
2024
PARSIFAL
Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer
BREAST
(Journal) The best
2024
PECATI
PECATI: A phase 2 trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma
THYMIC
ESMO
2024
ZZFIRST
First results from ZZFIRST: a randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
PROSTATE
ESMO
2024
CALADRIO
Profiling the gut and oral microbiota of hormone-receptor positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin
Breast
(Journal) Microbiome Research Reports
2024
METALLICA
Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial
BREAST
(Journal) eClinical Medicine
2024
DEBBRAH
Trastuzumab Deruxtecan in Patients with Central Nervous System Involvement from HER2-Positive Breast Cancer: The DEBBRAH Trial
BREAST
(Journal) Neuro-Oncology
2023
Other MEDSIR related articles
